Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Apellis Pharmaceuticals (APLS) EBIAT (2020 - 2025)

Apellis Pharmaceuticals has reported EBIAT over the past 6 years, most recently at -$59.0 million for Q4 2025.

  • Quarterly results put EBIAT at -$59.0 million for Q4 2025, down 62.16% from a year ago — trailing twelve months through Dec 2025 was $22.4 million (up 111.31% YoY), and the annual figure for FY2025 was $22.4 million, up 111.31%.
  • EBIAT for Q4 2025 was -$59.0 million at Apellis Pharmaceuticals, down from $215.7 million in the prior quarter.
  • Over the last five years, EBIAT for APLS hit a ceiling of $215.7 million in Q3 2025 and a floor of -$219.2 million in Q2 2021.
  • Median EBIAT over the past 5 years was -$130.5 million (2022), compared with a mean of -$105.1 million.
  • Biggest five-year swings in EBIAT: crashed 289.02% in 2021 and later skyrocketed 475.52% in 2025.
  • Apellis Pharmaceuticals' EBIAT stood at -$147.9 million in 2021, then fell by 12.21% to -$166.0 million in 2022, then skyrocketed by 46.64% to -$88.6 million in 2023, then surged by 58.96% to -$36.4 million in 2024, then tumbled by 62.16% to -$59.0 million in 2025.
  • The last three reported values for EBIAT were -$59.0 million (Q4 2025), $215.7 million (Q3 2025), and -$42.2 million (Q2 2025) per Business Quant data.